Moolec Science (MLECW) Long-Term Deferred Tax (2023 - 2025)
Moolec Science (MLECW) posted Long-Term Deferred Tax of -$15.8 million for Q2 2025, up 21.26% sequentially from -$20.0 million in Q2 2024, and up 21.26% YoY from -$13.0 million in Q2 2024.
Moolec Science (MLECW) Long-Term Deferred Tax (2023 - 2025) Analysis & Trends
Moolec Science has reported Long-Term Deferred Tax for 3 years, with the latest figure at -$15.8 million in Q2 2025.
- Quarterly Long-Term Deferred Tax rose 21.26% year-over-year to -$15.8 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was -$15.8 million (up 21.26% YoY) and the FY2025 annual result came in at -$15.8 million, up 21.26% from the prior year.
- Long-Term Deferred Tax rose to -$15.8 million in Q2 2025 per MLECW's latest filing, from -$20.0 million in the prior quarter.
- Over five years, Long-Term Deferred Tax peaked at -$15.8 million in Q2 2025 and troughed at -$24.8 million in Q2 2023.
- A 3-year average of -$20.2 million and a median of -$20.0 million in 2024 frame the typical range for Long-Term Deferred Tax.
- The sharpest annual moves came in 2024 and 2025: Long-Term Deferred Tax increased 19.38% in 2024, then advanced 21.26% in 2025.
- Over 3 years, Long-Term Deferred Tax stood at -$24.8 million in 2023, then climbed by 19.38% to -$20.0 million in 2024, then grew by 21.26% to -$15.8 million in 2025.
- According to Business Quant data, Long-Term Deferred Tax over the past three periods registered -$15.8 million, -$20.0 million, and -$24.8 million for Q2 2025, Q2 2024, and Q2 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Moolec Science | 8,617.72 | -1.19 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -15.77 Mn |
| Jun 30, 2024 | -20.02 Mn |
| Jun 30, 2023 | -24.84 Mn |